MicroPort CardioFlow Medtech (HKG:2160) expects to record a net loss of no more than $25 million for the first half of 2026, according to a Tuesday filing with the Hong Kong Stock Exchange.
The company also expects to post revenue of not less than $153 million for the period.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.